Stock prices
CAR-T Therapies Disappoint in Solid Tumors, Shares of Juno and Kite Drop
Patients with advanced cancers may have a limited option for CAR-T cellular therapies in solid tumors after a recent study revealed disappointing results. The study, conducted by the University of Pennsylvania and Novartis, used CAR-T therapies to target mesothelin, a protein found on some solid-tumor cancers. Although the therapy was